Adlai Nortye Group (ANL) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed MeiraGTx (MGTX) over the past year, gaining 796.5% versus a gain of 27.1%. MeiraGTx is the larger company by market cap ($1.01 billion vs $998.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | MGTX |
|---|---|---|
| Share price | $15.51 | $10.50 |
| Market cap | $998.81M | $1.01B |
| 1-day change | +10.39% | -2.96% |
| YTD return | +992.25% | +32.08% |
| 1-year return | +796.53% | +27.12% |
| 5-year return | — | -26.47% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-0.66 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $15.35 |
| 52-week low | $0.879 | $6.62 |
| Distance from 52-week high | -10.09% | -31.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.20% | +164.29% |
| Average volume | 187.30K | 792.38K |
| Shares outstanding | 58.73M | 96.04M |
| Employees | 109 | 393 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed MGTX by 769.4 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Healthcare · Biotechnology · 393 employees
ANL vs MGTX FAQ
Which is bigger, Adlai Nortye Group or MeiraGTx?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.01B compared with $998.81M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or MGTX?
ANL returned +796.53% over the past 12 months, compared with +27.12% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.